Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.

Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo-Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL.

Vaccine. 2012 May 30;30 Suppl 2:B46-51. doi: 10.1016/j.vaccine.2011.12.112. Epub 2012 Jan 9.

PMID:
22230584
2.

Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso.

Bentsi-Enchill AD, Zongo I, Khamassi S, Pless R, Thombiano R, Tiéndrebéogo S, Nelson CB, Duclos P.

Vaccine. 2007 Sep 3;25 Suppl 1:A72-8. Epub 2007 May 7.

PMID:
17544552
3.

[Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].

Yaméogo TM, Breugelmans JG, Kambou JL, Badolo O, Tiendrebéogo S, Traoré E, Avokey F, Yactayo S.

Med Trop (Mars). 2009 Aug;69(4):320-1. French.

PMID:
19725376
4.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
5.

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.

Ateudjieu J, Stoll B, Nguefack-Tsague G, Yakum MN, Mengouo MN, Genton B.

Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1170-1178. doi: 10.1002/pds.4027. Epub 2016 May 13.

PMID:
27174237
6.

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.

Chaibou MS, Bako H, Salisou L, Yaméogo TM, Sambo M, Kim SH, Djingarey MH, Zuber PL, Perea WA, Pezzoli L.

Vaccine. 2012 Jul 27;30(35):5229-34. doi: 10.1016/j.vaccine.2012.06.006. Epub 2012 Jun 16.

PMID:
22709955
7.

Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.

Meyer SA, Kambou JL, Cohn A, Goodson JL, Flannery B, Medah I, Messonnier N, Novak R, Diomande F, Djingarey MH, Clark TA, Yameogo I, Fall A, Wannemuehler K.

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

PMID:
25636915
8.

Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1022-4.

9.

Annual report: surveillance of adverse events following immunisation in Australia, 2009.

Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI.

Commun Dis Intell Q Rep. 2010 Sep;34(3):259-76.

11.

Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac™): a randomized controlled trial.

Ateudjieu J, Stoll B, Nguefack-Tsague G, Tchangou C, Genton B.

Vaccine. 2014 Sep 29;32(43):5662-8. doi: 10.1016/j.vaccine.2014.08.012. Epub 2014 Aug 23.

PMID:
25160064
12.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

13.

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, Böthe M, Perea W, Niedrig M, Gessner BD, Yactayo S; YF AEFI group.

Vaccine. 2013 Apr 3;31(14):1819-29. doi: 10.1016/j.vaccine.2013.01.054. Epub 2013 Feb 7.

PMID:
23395587
14.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
15.

Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C, Edwards KM, Klein J, Klein NP, LaRussa P, Sparks R, Jakob K.

Vaccine. 2012 Nov 26;30(50):7253-9. doi: 10.1016/j.vaccine.2012.09.074. Epub 2012 Oct 9.

PMID:
23063829
16.

Surveillance of adverse events following immunisation: Australia 2002 to 2003.

Lawrence G, Boyd I, McIntyre P, Isaacs D.

Commun Dis Intell Q Rep. 2004;28(3):324-38.

17.

Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.

Kristiansen PA, Ba AK, Ouédraogo AS, Sanou I, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Saga IM, Misegades L, Clark TA, Préziosi MP, Caugant DA.

BMC Infect Dis. 2014 Dec 4;14:663. doi: 10.1186/s12879-014-0663-4.

18.

Annual report: Surveillance of adverse events following immunisation in Australia, 2005.

Lawrence G, Boyd I, McIntyre P, Isaacs D.

Commun Dis Intell Q Rep. 2006;30(3):319-33.

19.

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.

Diomandé FV, Yaméogo TM, Vannice KS, Preziosi MP, Viviani S, Ouandaogo CR, Keita M, Djingarey MH, Mbakuliyemo N, Akanmori BD, Sow SO, Zuber PL.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S459-66. doi: 10.1093/cid/civ599.

20.

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine.

Kristiansen PA, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Thomas JD, Clark TA, Laforce M, Caugant DA.

BMC Infect Dis. 2013 Aug 2;13:363. doi: 10.1186/1471-2334-13-363.

Supplemental Content

Support Center